Ashok K Malla Selected Research

Polytetrafluoroethylene (Teflon)

4/2022	Severe childhood trauma and emotion recognition in males and females with first-episode psychosis.
1/2022	Manualized group cognitive behavioral therapy for social anxiety in first-episode psychosis: a randomized controlled trial.
9/2021	Dynamic association of the first identifiable symptom with rapidity of progression to first-episode psychosis.
1/2021	Adipose tissue dysregulation at the onset of psychosis: Adipokines and social determinants of health.
1/2021	Impact of childhood trauma on positive and negative symptom remission in first episode psychosis.
1/2021	Timing, Distribution, and Relationship Between Nonpsychotic and Subthreshold Psychotic Symptoms Prior to Emergence of a First Episode of Psychosis.
1/2020	Do Unremitted Psychotic Symptoms Have an Effect on the Brain? A 2-Year Follow-up Imaging Study in First-Episode Psychosis.
1/2020	Intersection of verbal memory and expressivity on cortical contrast and thickness in first episode psychosis.
12/2019	Structural Associations of Cortical Contrast and Thickness in First Episode Psychosis.
12/2019	The effect of second-generation antipsychotics on basal ganglia and thalamus in first-episode psychosis patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ashok K Malla Research Topics

Disease

58	Psychotic Disorders (Schizoaffective Disorder) 04/2022 - 04/2002
7	Schizophrenia (Dementia Praecox) 10/2014 - 04/2002
1	Wounds and Injuries (Trauma) 04/2022
1	Insulin Resistance 01/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Cerebral Cortical Thinning 01/2014
1	Mood Disorders (Mood Disorder) 10/2013
1	Anxiety Disorders (Anxiety Disorder) 10/2013
1	Substance-Related Disorders (Drug Abuse) 10/2013
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 11/2011
1	Mental Disorders (Mental Disorder) 10/2009
1	Prodromal Symptoms 12/2005

Drug/Important Bio-Agent (IBA)

47	Polytetrafluoroethylene (Teflon)FDA Link 04/2022 - 09/2003
10	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 04/2002
6	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2019 - 09/2008
2	CDRI 85-287 (PEPP)IBA 01/2017 - 07/2011
2	Pharmaceutical PreparationsIBA 10/2014 - 01/2007
2	A-factor (Streptomyces)IBA 09/2008 - 01/2005
1	AdipokinesIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2019
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 03/2015
1	Biomarkers (Surrogate Marker)IBA 03/2015
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 10/2009
1	Choline (Choline Chloride)IBA 07/2004
1	N-acetylaspartate (N-acetyl aspartate)IBA 07/2004

Therapy/Procedure

2	Treatment Delay 06/2007 - 09/2003
1	Continuity of Patient Care 07/2011
1	Patient Readmission 04/2002